羟考酮控释片(奥施康定)缓解癌痛及改善肺癌患者生活质量的观察  

CONTROLLED-RELEASE OXYCODONE RELIEVES CANCER PAIN AND IMPROVES QUALITY OF LIFE OF LUNG CANCER PATIENTS

作　　者：黄蕾[1] 吴海鹰[1] 刘俊玲[1] 胡晓晔[1] 戴文清[1] 段海波[1] 

机构地区：[1]中山大学肿瘤防治中心化疗科,广州510060

出　　处：《中国疼痛医学杂志》2007年第2期88-91,共4页Chinese Journal of Pain Medicine

基　　金：广州市科技局基金资助项目(编号2002J1-C0321)

摘　　要：目的：评价羟考酮控释片在治疗慢性癌痛中的疗效及安全性。同时观察伴随疼痛的肺癌患者在接受奥施康定镇痛治疗后其生活质量的改善情况。方法：疼痛的评价采用0-10数字疼痛强度评分法，并记录剂量滴定达稳态时间和维持剂量。采用生活质量量表EORT CQLQ-C30（V3．0）中文版对其中28名肺癌患者治疗前后的生活质量进行了评估。结果：入组的48例患者中，有46例可评价疗效及安全性。其中42例（87．5％）患者达到了满意的疼痛缓解，平均滴定达稳态时间为2．1天。用药期间，25名（52．1％）患者曾经发生至少1种不良反应。在疼痛缓解的同时，大多数肺癌患者的生活质量得到了改善。结论：奥施康定用于治疗中重度癌性疼痛是安全有效的；它能改善肺癌疼痛病人的生活质量。Objective： To evaluate the efficacy and safety of oral controlled-release （CR） oxycodone in patients with cancer pain, and to observe the improvement of quality of life （QOL） in lung cancer patients after CR oxycodone treatment. Methods： The pain intensity was measured by numerial rating scale （NRS）. The length of time and the dose needed to attain stable and adequate pain control were evaluated. QOL were assessed in 28 lung cancer patients, using EORTC QLQ-C30 （Chinese version 3 ）. Results ： Of 48 patients enrolled, 46 patients were evaluated for efficacy and tolerability. 42 patients （42 out of 48, 87.5% ） attained stable, adequate pain control. The mean length of titration time was 2.1 days. During CR oxycodone treatment, 25 （52.1% ） reported at least one adverse effect. Followed the reduced of the pain intensity, the QOL of most lung cancer patients was improved. Conclusion ： Oral CR oxycodone is effective and safe for the management of cancer patients with moderate to severe pain, and it improves the QOL of lung cancer patients.

关 键 词：羟考酮控释片 疼痛治疗 生活质量 肺癌 

分 类 号：R730.5[医药卫生—肿瘤] R734.2[医药卫生—临床医学]